ClearPoint Neuro (CLPT) Change in Accured Expenses (2011 - 2026)

ClearPoint Neuro has disclosed Change in Accured Expenses across 15 years of filings, most recently posting -$437000.0 for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$437000.0, up 84.84% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.1 million (down 539.77% YoY), and the FY2025 annual result was -$7.5 million, down 342.19% from the prior year.
• Change in Accured Expenses came in at -$437000.0 for Q1 2026 at ClearPoint Neuro, up from -$6.3 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.7 million in Q4 2024 to a low of -$6.3 million in Q4 2025.
• The 5-year median for Change in Accured Expenses is $374000.0 (2023), against an average of -$230000.0.
• Peak annual rise in Change in Accured Expenses reached 443.4% in 2022, while the deepest fall reached 1181.48% in 2022.
• ClearPoint Neuro's Change in Accured Expenses stood at $336000.0 in 2022, then advanced by 11.31% to $374000.0 in 2023, then soared by 363.1% to $1.7 million in 2024, then tumbled by 461.95% to -$6.3 million in 2025, then surged by 93.03% to -$437000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$437000.0 (Q1 2026), -$6.3 million (Q4 2025), and $693000.0 (Q3 2025), per Business Quant data.